Medetomidine test strip, for forensic and harm reduction applications

Order through Avantor/VWR: Box of 25

Product Overview

The Instanosis Medetomidine Test Strip is a highly sensitive, rapid lateral flow assay developed with NIH funding and manufactured in the USA for forensic, harm reduction, and laboratory applications. Featuring a specialized analytical detection cut-off of 50 ng/mL, this premium immunoassay strip is 20 times more sensitive than standard alternatives on the market. This breakthrough limit of detection enables field teams and researchers to successfully identify the potent veterinary sedative medetomidine while utilizing less than 1/10th of the sample volume required by legacy testing products, preserving valuable primary forensic compounds.

Technical Specifications & Key Data

The Instanosis standalone immunoassay strip provides precise, high-affinity detection for emerging alpha-2 adrenergic receptor agonists in toxicological screening environments:

• Target Analyte: Medetomidine (including high cross-reactivity optimization for both dexmedetomidine and levomedetomidine enantiomers).

• Analytical Cut-off Level: 50 ng/mL (Engineered to be 20 times more sensitive than alternative commercial field tests).

• Sample Volume Requirement: Requires 90% less sample amount ( 1/10th of competitive baseline requirements), protecting the integrity of trace forensic evidence.

• Assay Run Time: Clear, visible qualitative results within 5 minutes.

• Origin & Quality Standards: Proudly Made in the U.S. under rigorous quality management baselines.

• Quality Credential: Manufactured in an FDA-registered facility compliant with FDA QMSR Quality Standard.

Public Health & Toxicological Significance

Medetomidine is a synthetic veterinary sedative that has increasingly emerged as a severe adulterant within the illicit fentanyl supply chain.

• Potency Profile: Medetomidine operates with a clinical potency estimated to be 200 to 300 times greater than xylazine, dramatically increasing the risk of severe bradycardia, profound central nervous system depression, and treatment-resistant respiratory failure.

• Naloxone Limitations: Because medetomidine is not an opioid, its sedative effects cannot be reversed by naloxone (Narcan). Rapid field screening tools are vital to inform emergency response personnel and community outreach networks of localized exposure hazards.

Frequently Asked Questions (FAQ)

• Q1: What is the exact detection threshold for the Instanosis Medetomidine test strip?

A: The technical cut-off concentration is set at 50 ng/mL. This limit of detection makes the assay roughly 20 times more sensitive than other general field tests currently available on the market.

• Q2: Why does this test strip require so little sample volume?

A: Our lateral flow immunoassays utilizes advanced, high-affinity antibodies. As a result, users need less than 1/10th of the sample volume required by standard market alternatives, keeping your primary research or forensic samples intact.

• Q3: Can this strip detect both forms of medetomidine?

A: Yes. The immunoassay matrix is optimized to recognize both chemical isomers (dexmedetomidine and levomedetomidine) found within illicitly sourced racemic mixtures, ensuring a lower rate of false negatives.

• Q4: Is this product manufactured in the United States?

A: Yes. The Instanosis Medetomidine test strip is manufactured entirely in the USA, in an FDA-registered facility compliant with FDA QMSR Quality Standard.

• Q5: Can public health departments buy this item through standard laboratory distributors?

A: Yes. In addition to direct corporate purchasing, organizations can procure the Instanosis Box of 25 strips through our established distribution listings on Avantor/VWR.

• Q6: Can these test strips be used for patient diagnostics or clinical settings?

A: No. This product is strictly designed, labeled, and intended for forensic investigations, harm reduction surveillance, and laboratory research applications only.

Click to download Medetomidine test strip instruction